Publications by authors named "Alayde Vieira Wanderley"

Background: Acute Lymphoblastic Leukemia (ALL) is a neoplasm of the hematopoietic system characterized by a clonal expansion of abnormal lymphocyte precursor cells. ALL is the most common form of cancer in children, but despite advances in treatment, it can still be fatal. Ethnic differences influence survival rates, and genomic ancestry plays an important role, especially in mixed-race populations such as Latin America.

View Article and Find Full Text PDF
Article Synopsis
  • Acute lymphoblastic leukemia (ALL) is the most common cancer in children, and certain genetic variants (SNVs) may influence how patients respond to treatment and experience side effects.
  • The study focused on 25 specific SNVs in genes related to microRNA in 77 patients from the Brazilian Amazon, utilizing the TaqMan OpenArray™ Genotyping System for analysis.
  • Results indicated some SNVs increased the risk of neurological and gastrointestinal toxicities, while others provided protection, highlighting the potential to use these genetic markers to better understand and manage treatment-related toxicities in ALL patients.
View Article and Find Full Text PDF

Unlabelled: Acute lymphoblastic leukemia (ALL) is the most common cancer during childhood, representing about 30-35% of cases. Its etiology is complex and not fully understood. ALL is influenced by genetic variants, and their frequencies (Fq) vary in different ethnic groups, which consequently could influence the epidemiology of this cancer worldwide.

View Article and Find Full Text PDF

Acute Lymphoblastic Leukemia (ALL) is a neoplasm of the hematopoietic system defined as a clonal expansion of an abnormal lymphoid precursor cell. It mostly affects children under five years of age and is the most common tumor to afflict pediatric patients. The expression of the human telomerase gene () in patients with ALL has been studied as a biomarker and could become a new therapeutic target.

View Article and Find Full Text PDF

Objective: To assess the performance of Pediatric Risk of Mortality (PRISM) III and Pediatric Index of Mortality (PIM) 2 scores in the pediatric intensive care unit.

Methods: A retrospective cohort study. Data were retrospectively collected from medical records of all patients admitted to the pediatric intensive care unit of a cancer hospital from January 2017 to June 2018.

View Article and Find Full Text PDF

Aurora kinases (AURKA and AURKB) are mitotic kinases with an important role in the regulation of several mitotic events, and in hematological malignancies, AURKA and AURKB hyperexpression are found in patients with cytogenetic abnormalities presenting a unfavorable prognosis. The aim of this study was evaluated the mRNA expression profile of pediatric Acute Lymphoblastic Leukaemia (ALL) patients and the efficacy of two AURKA and AURKB designed inhibitors (GW809897X and GW806742X) in a leukemia cell line as a potential novel therapy for ALL patients. Cellular experiments demonstrated that both inhibitors induced cell death with caspase activation and cell cycle arrest, however only the GW806742X inhibitor decreased with more efficacy AURKA and AURKB expression in K-562 leukemia cells.

View Article and Find Full Text PDF

Acute lymphoblastic leukemia (ALL) is the leading cause of death from pediatric cancer worldwide. However, marked ethnic disparities are found in the treatment of childhood ALL with less effective results and higher mortality rates being obtained in populations with a high level of Native American ancestry. Genetic variations of the patient can affect resistance to ALL chemotherapy and potentially play an important role in this disparity.

View Article and Find Full Text PDF

Copy number variations (CNVs) analysis may reveal molecular biomarkers and provide information on the pathogenesis of acute lymphoblastic leukemia (ALL). We investigated the gene copy number in childhood ALL by microarray and select three new recurrent CNVs to evaluate by real-time PCR assay: , and were selected due to high frequency of CNVs in ALL samples and based on their potential biological functions in carcinogenesis described in the literature. deletion was associated with patients with chromosomal translocations and is a potential tumor suppressor; and may act as an oncogene despite having a paradoxical behavior in carcinogenesis.

View Article and Find Full Text PDF
Article Synopsis
  • - Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer, but treatment outcomes vary among different ethnic groups, particularly showing lower success rates in children with high Native American ancestry.
  • - A study analyzed 27 genetic markers related to ALL treatment in Amerindian populations from the Brazilian Amazon and compared these to data from five continents, revealing significant differences in marker frequencies.
  • - The unique genetic profile of the indigenous Amazonian population suggests they may require tailored treatment strategies for ALL due to their distinct pharmacogenomic variants.
View Article and Find Full Text PDF

Introduction: The nudix hydrolase 15 (NUDT15) gene acts in the metabolism of thiopurine, by catabolizing its active metabolite thioguanosine triphosphate into its inactivated form, thioguanosine monophosphate. The frequency of alternative NUDT15 alleles, in particular those that cause a drastic loss of gene function, varies widely among geographically distinct populations. In the general population of northern Brazilian, high toxicity rates (65%) have been recorded in patients treated with the standard protocol for acute lymphoblastic leukemia, which involves thiopurine-based drugs.

View Article and Find Full Text PDF

Acute Lymphoblastic Leukemia (ALL) is the most common childhood neoplasia. Studies have shown that susceptibility to ALL may be modulated by genetic variables. Our study investigated 21 genetic variants in the susceptibility of the population of the Brazilian Amazon region to B-cell ALL.

View Article and Find Full Text PDF

The treatment of Acute Lymphoblastic Leukemia (ALL) in children has a high clinical success rate, although toxicological complications are frequent, and often result in the interruption of the treatment. Various studies have shown that toxicities resulting from the treatment are influenced by pharmacogenetic variants. Most of this research has focused on relatively homogeneous populations, and the influence of these variants in highly admixed populations, such as that of Brazil, is still poorly understood.

View Article and Find Full Text PDF